News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Phase 3 vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (PAD) (Protocol BAY 59-7939/17454)

Study Status:

Closed for enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

Purpose of the study is to evaluate the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.

Information: 

Principal Investigator
Mahesh Changlani, MD
Sponsor
Bayer Health Care Pharmaceuticals, Inc.
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram